Results 121 to 130 of about 44,621 (163)

Enhancing adoptive immunotherapy of cancer

Expert Opinion on Biological Therapy, 2010
Conventional therapies, including surgery, chemotherapy and radiotherapy have contributed much to cancer treatment. However, these treatment modalities fail in a large proportion of patients, and there is a great need for effective alternate therapies.
Jennifer A, Westwood, Linda J, Berry, Leanne Xj, Wang, Connie Pm, Duong, Hollie J, Pegram, Phillip K, Darcy, Michael H, Kershaw   +6 more
openaire   +2 more sources

Adoptive immunotherapy of HCMV infection

Cytotherapy, 2007
Human cytomegalovirus (HCMV) infection or reactivation is a frequent cause of morbidity and mortality in immunocompromised individuals such as transplant recipients. Primary HCMV infection or reactivation of HCMV from latency is mostly asymptomatic in immunocompetent individuals and is controlled by the host's cell-mediated immune response.
M, Kapp, S M, Tan, H, Einsele, Gu, Grigoleit   +3 more
openaire   +2 more sources

Costimulatory approaches to adoptive immunotherapy

Current Opinion in Oncology, 1998
Costimulation is critical for induction of full T-cell effector function, and thus represents an attractive immunotherapeutic approach for the treatment of cancer. This review examines these approaches, including ex vivo T-cell expansion, systemic "delivery" of constimulation, tumors transduced or transfected with costimulatory ligands, and vaccine ...
D N, Liebowitz, K P, Lee, C H, June
openaire   +2 more sources

Adoptive immunotherapy against sarcomas

Expert Opinion on Biological Therapy, 2014
Conventional treatments reached an unsatisfactory therapeutic plateau in the treatment of advanced unresectable bone and soft tissue sarcomas that remain an unsolved medical need. Several evidences support the concept that adoptive immunotherapy may effectively integrate within the complex and multidisciplinary treatment of sarcomas.In this work we ...
Mesiano, Giulia, Leuci, Valeria, Giraudo, Lidia, Gammaitoni, Loretta, Carnevale Schianca, Fabrizio, Cangemi, Michela, Rotolo, Ramona, Capellero, Sonia, Pignochino, Ymera, Grignani, Giovanni, Aglietta, Massimo, Sangiolo, Dario   +11 more
openaire   +2 more sources

Adoptive Immunotherapy of Ovarian Carcinoma

Gynecologic Oncology, 2002
info:eu-repo/semantics ...
de Gramont, Aimery, Gangji, Diamon, Louvet, Christophe, Garcia, Monserrat, Tardy, D., Romet-Lemonne, Jean-Loup   +5 more
openaire   +2 more sources

Adoptive immunotherapy of urologic tumors

1989
The treatment of humans with advanced cancer represents a major therapeutic challenge. One approach to treating metastatic cancer is immunotherapy, which can be classified into active and passive categories. Active immunotherapy refers to the immunization of the tumor-bearing host with materials that attempt to induce in the host a state of immune ...
A, Belldegrun, S A, Rosenberg
openaire   +2 more sources

Adoptive Immunotherapy of Advanced Melanoma

Current Treatment Options in Oncology, 2012
Adoptive cell therapy (ACT) has emerged as an effective therapy for patients with metastatic melanoma. Since the first introduction of the protocol in 1988 [1], major improvements have been achieved with response rates of 40%-72% among patients who were resistant to previous treatment lines.
Ronnie, Shapira-Frommer, Jacob, Schachter   +1 more
openaire   +2 more sources

Technological advances in adoptive immunotherapy

Drugs of Today, 2005
Adoptive immunotherapy is an attractive and elegant strategy for treating a variety of life-threatening diseases. Several approaches have been developed to generate antigen-specific CD4+ and CD8+ T cells for adoptive T-cell therapy in cancer and infectious diseases.
Mathias, Oelke, Christine, Krueger, Jonathan P, Schneck   +2 more
openaire   +2 more sources

Adoptive Immunotherapy for Hodgkin's Lymphoma

International Journal of Hematology, 2006
Adoptive transfer of tumor-specific T-cells is an attractive strategy for the treatment of patients with refractory or relapsed Hodgkin's lymphoma. However, Hodgkin's lymphomas possess a range of tumor-evasion mechanisms, which must be overcome before the full potential of immunotherapies can be achieved.
Alana A, Kennedy-Nasser, Catherine M, Bollard, Cliona M, Rooney   +2 more
openaire   +2 more sources

An artificial solution for adoptive immunotherapy

Trends in Biotechnology, 2003
Abstract Adoptive immunotherapy is a promising strategy in the battle against cancer and infectious diseases and the recently developed artificial antigen-presenting cell (aAPC) overcomes several obstacles for this therapy. The aAPC recapitulates the natural in vivo antigen-presenting cell (APC)–T cell interactions by coupling human leukocyte ...
openaire   +2 more sources